Penumbra's thrombectomy growth and new products show promise, but high valuation at 7x 2025 revenue tempers appeal for GARP ...

Once the intravenous tPA infusion was started, the patient was transferred via air ambulance to a comprehensive stroke center. On arrival (3 h 17 min after symptom onset) the patient remained ...

Penumbra reported Q4 sales of $315.52 million, up 10.8% Y/Y, beating estimates of $311.55 million. U.S. thrombectomy sales jumped 27.3%, driving global growth of 15.4%. Get 5 stock picks ...

The MERCI®retrieval device and the Penumbra Stroke System®are US FDA-approved endovascular devices for thrombectomy in acute ischemic stroke due to cerebral vascular occlusions. Widespread ...

But he noted Penumbra didn't offer any insight into its Thunderbolt product. Thunderbolt is in testing for patients with acute ischemic stroke. Thunderbolt "could become a significant growth ...

Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business ... enormous potential to further expand its leadership in stroke intervention outside the United States with SENDit and ...

Clinical Outcome in Acute Stroke Treatment After Image Guided Patient Selection for Interventional Revascularization Therapy (START) This industry-sponsored study was designed to assess the safety and ...

Penumbra disclaims any duty to update or revise ... Shifting to our neurovascular business. Our U.S. stroke thrombectomy business once again posted strong results with revenue accelerating versus ...